Medical Innovation Bill

The Academy is monitoring the passage of the Medical Innovation Bill.

Ongoing

The Academy has submitted a response to the Department of Health’s consultation on the Medical Innovation Bill, commonly known as the Saatchi Bill, jointly with the Medical Research Council and the Wellcome Trust. The Bill aims to ensure that clinicians can use experimental treatments without fear of litigation, providing this is done 'responsibly' and with consent.

While the Academy and partner organisations are supportive of efforts to encourage innovation in healthcare, we are concerned that the Bill may have implications for patients and research. For instance, we are concerned that the Bill may discourage patients from participating in clinical trials, thereby unintentionally allowing uncontrolled experimentation. We believe that medical innovation is best achieved through a robust research framework where the safety and efficacy of novel treatments can be thoroughly tested.

In our response, we highlight that the Bill does not address the underlying issues of bureaucracy and funding of novel treatments, which are major barriers to medical innovation. We also raise our concerns about the lack of provisions in the Bill for any form of follow-up or data collection to consider the effects of innovative treatments, which could lead to some patients continuing to receive untested, ineffective or potentially harmful treatments. 

Daniel Turnberg Travel Fellowship Alumni Conference 2019

Book Now

The Academy of Medical Sciences and The Lancet International Health Lecture 2019

Book Now

Annual Fellows' Meeting and Dinner 2019

Book Now
View more
 
 
 
 
 
 
FB Twitter Instagram Youtube